Exciting Developments in Lymphoma (Lymphnode Cancer) and Myeloma ... EIN News (press release) To date, up to 80% of patients with the most common subtype of malignant lymphoma (diffuse large B-cell lymphoma), are cured of this aggressive disease by chemotherapy, in combination with the anti-lymphoma antibody Rituximab. Unfortunately, young ... |
